Charles River Laboratories

NYSE: CRL ↗ $202.07 USD ~$8B MCAP

#Preclinical research services #Safety assessment #Cell and gene therapy manufacturing #Biologics testing #Microbial identification #Clinical trial support

Charles River Laboratories is a major contract research organization (CRO) providing preclinical and clinical laboratory services for drug development. Founded in 1947, the company helps expedite discovery, safety assessment, and manufacturing of novel drugs and medical devices.

Company Info

Sector: CRO / Lab Services

Headquarters: Wilmington, Massachusetts, USA

Founded: 1947

Website: www.criver.com/

Upcoming Milestones & Key Dates

2026 Q3

Earnings

Q2 2026 earnings release

2026 Q4

Earnings

Q3 2026 earnings release

Clinical Development Pipeline

Preclinical services portfolio (RMS segment)

Target: Service platform

Drug safety / efficacy assessment

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Manufacturing services (CDMO segment)

Target: Service platform

Cell and gene therapy, biologics manufacturing

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Research models & services (RMS)

Target: Service platform

Animal models for research

Preclinical

Phase 1

Phase 2

Phase 3

Approved

James C. Foster

Chairman, President & CEO

Michael Gunnar Knell

Corporate Vice President & Chief Financial Officer

William D. Barbo

Corporate Vice President, Chief Commercial Officer

Careers & Job Openings

See all open roles

Multiple Departments

Global (Wilmington MA + 150+ sites)

Apply Now →